Current practice in the management of ocular toxoplasmosis

• Published in: British journal of ophthalmology Vol. 107; no. 7; pp. 973 - 979
• Main Authors: Furtado, João M, Bodaghi, Bahram, Smith, Justine R, Agarwal, Aniruddha, Ahn, Seong Joon, Alvarez, Carlos, Arcinue, Cheryl, Fernando Arevalo, J, Arrieta-Bechara, Cesar, Artaraz, Joseba, Ata, Ashraf, Ayuso, Viera Kalinina, Babu, Kalpana, Bansal, Reema, Becker, Matthias, Bigornia-Arriola, Lyll Karen, Blanco-Esteban, Ana, Carreño, Ester, Chang, Yo-Chen, Davis, Janet, Denisova, Ekaterina, Simone, Luca De, Díaz-Cascajosa, Jesús, Dorokhova, Oleksandra, Duarte, Gonzalo, Elyashiv, Sivan, Emami-Naeini, Parisa, Fortin, Eric, Funk, Marion, Garweg, Justus, Géhl, Zsuzsanna, Gepstein, Raz, Gimenez, Alex, Gugleta, Konstantin, Gupta, Vishali, Gurbaxani, Avinash, Habot-Wilner, Zohar, Hall, Anthony, Hosseini, Maryam, Hunchangsith, Boonsiri, Hwang, De-Kuang, Hwang, Yih Shiou, Iriqat, Salam Saeb, Islam, Bulbul, Iwahashi, Chiharu, Julien, Bouleau, Kaburaki, Toshikatsu, Kadayifçilar, Sibel, Kansupada, Kashyap, Kao, Tzu-En, Kaplan, Alexander, Keino, Hiroshi, Kempen, John H, Kim, Seong-Woo, Lai, Timothy Y Y, Larrocea, Maria IGO, Lee, Christopher Seungkyu, Lee, Ji Hwan, Lobo-Chan, Ann-Marie, Mahendradas, Padmamalini, Makhoul, Dorine, Marcos, Irene Redondo, Martínez-Costa, Lucía, McCluskey, Peter, Mili-Boussen, Ilhem, Mochizuki, Manabu, Nakai, Kei, Nakhoul, Nakhoul, Nguyen, Quan Dong, Ohno, Shigeaki, Okada, Annabelle A, Okhravi, Narciss, Özdal, Pinar, Özyazgan, Yılmaz, Paroli, Maria Pia, Partida, Jorge AA, Pichi, Francesco, Ramos, Stephanie Voorduin, Rauer, Ola, Relvas, Lia Judice, Rodriguez-Garcia, Alejandro, Sainz-de-la-Maza, Maite, Sen, Yuen Yew, Sheu, Shwu-Jiuan, Smith, Justine, Somkijrungroj, Thanapong, Sreekantam, Sreekanth, Sudharshan, Sridharan, Takeuchi, Masaru, Trittibach, Peter, Tugal-Tutkun, Ilknur, Utami, Anna Nur, Vadboncoeur, Julie, Os, Luc Van, Vazquez, Erika, Willermain, François, Wu, Lihteh, Yalçındağ, Nilüfer, Zborovska, Oleksandra
• Format: Journal Article
• Language: English
• Published: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.07.2023; BMJ Publishing Group LTD
• Subjects: Anti-Bacterial Agents - therapeutic use; Cataracts; Chorioretinitis - diagnosis; Clinical science; Congenital diseases; Disease; Glaucoma; Health care; Humans; Hypertension; infection; Infections; inflammation; Medical personnel; Patients; Protozoa; retina; Serology; Steroids; Surveys and Questionnaires; Toxoplasmosis, Ocular - diagnosis; Toxoplasmosis, Ocular - drug therapy; Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use; Australia; inflammation; retina; infection
• ISSN: 0007-1161; 1468-2079
• DOI: 10.1136/bjophthalmol-2022-321091

BackgroundOcular toxoplasmosis is common across all regions of the world. Understanding of the epidemiology and approach to diagnosis and treatment have evolved recently. In November 2020, an international group of uveitis-specialised ophthalmologists formed the International Ocular Toxoplasmosis Study Group to define current practice.Methods192 Study Group members from 48 countries completed a 36-item survey on clinical features, use of investigations, indications for treatment, systemic and intravitreal treatment with antiparasitic drugs and corticosteroids, and approach to follow-up and preventive therapy.ResultsFor 77.1% of members, unilateral retinochoroiditis adjacent to a pigmented scar accounted for over 60% of presentations, but diverse atypical presentations were also reported. Common complications included persistent vitreous opacities, epiretinal membrane, cataract, and ocular hypertension or glaucoma. Most members used clinical examination with (56.8%) or without (35.9%) serology to diagnose typical disease but relied on intraocular fluid testing—usually PCR—in atypical cases (68.8%). 66.1% of members treated all non-pregnant patients, while 33.9% treated selected patients. Oral trimethoprim–sulfamethoxazole was first-line therapy for 66.7% of members, and 60.9% had experience using intravitreal clindamycin. Corticosteroid drugs were administered systemically by 97.4%; 24.7% also injected corticosteroid intravitreally, almost always in combination with an antimicrobial drug (72.3%). The majority of members followed up all (60.4%) or selected (35.9%) patients after resolution of acute disease, and prophylaxis against recurrence with trimethoprim–sulfamethoxazole was prescribed to selected patients by 69.8%.ConclusionOur report presents a current management approach for ocular toxoplasmosis, as practised by a large international group of uveitis-specialised ophthalmologists.